If your NAD+ has collapsed, you don’t have one tool — you have two competing peptide molecules, and most of the biohacking internet is using the wrong one for the wrong job. 5-Amino-1MQ and MOTS-c both promise to restore NAD+, both promise to drop bodyfat, both promise to extend healthspan. They are not interchangeable. One blocks NNMT in the cytoplasm. The other is a mitochondrial-DNA-encoded peptide that signals the nucleus. Confusing them will waste your money and your time.
I have run both. I have run them stacked. I have measured bloodwork on both. Here’s the actual breakdown.
Quick Summary
- 5-Amino-1MQ = NNMT inhibitor. Oral. Cheap. Best for sedentary fat-loss and metabolic syndrome.
- MOTS-c = 16-amino-acid mitochondrial-derived peptide. Injectable. Best for athletes, glucose disposal, and direct mitochondrial repair.
- Mechanism overlap is minimal. Stacking is rational.
- Bloodwork must include fasting insulin, HOMA-IR, A1c, and an NAD+ panel for either compound.
The NAD+ Problem Both Compounds Try to Solve
By age 50 your NAD+ is roughly half what it was at age 20. CD38 expression triples. The salvage pathway slows. The de novo pathway via tryptophan is too slow to matter. This is the substrate-collapse phase of aging, and it’s why mitochondrial output falls. Restoring NAD+ is the closest thing biohacking has to a master lever — but the question of how you restore it determines whether your strategy works.
The mainstream answer is NMN, NR, or NAD+ patches. Those are precursors. They work, partially, but they get destroyed in the gut, taxed by methylation, and a large fraction never reaches the mitochondria. 5-Amino-1MQ and MOTS-c attack different points in the same broken pathway.
5-Amino-1MQ: Plugging the NAD+ Drain
Nicotinamide N-methyltransferase (NNMT) is an enzyme that takes nicotinamide — the recyclable substrate that should be feeding NAD+ — and methylates it into 1-methylnicotinamide (MNA). That methylated waste product is excreted in urine. In obese adipose tissue, NNMT is up to fourfold overexpressed. Translation: your fat cells are actively burning your methyl pool to flush nicotinamide before it can be recycled into NAD+.
5-Amino-1MQ is a small-molecule NNMT inhibitor. It looks like the product of the reaction (1-MQ) with an amine bolted on at the 5-position. It binds the NNMT active site and shuts the enzyme down. Result: nicotinamide stops getting wasted, the methyl pool is preserved, and adipose NAD+ rises.
Animal data shows 5-Amino-1MQ:
- Reduces body weight by 10–13% in diet-induced obese mice without changing food intake [1].
- Increases white-adipose NAD+ by 80% within two weeks.
- Improves insulin sensitivity and lowers fasting glucose.
- Preserves the SAM:SAH methyl ratio, which has implications for everything from DNA methylation patterns to histamine clearance.
It is orally bioavailable. Half-life is short (3–4 hours). Dosing is typically 50–150 mg/day, split or single. There is no human registration trial yet — this is still in the gray-zone research-chemical category — but the rodent dossier is mature and the mechanism is exquisitely targeted.
MOTS-c: The Mitochondrial Telegram
MOTS-c is a 16-amino-acid peptide encoded inside the 12S rRNA region of mitochondrial DNA. It was discovered in 2015 and immediately rewrote the textbooks. Mitochondria don’t just generate ATP — they send peptide signals to the nucleus that govern metabolism. MOTS-c is the most studied of these mitochondrial-derived peptides.
Mechanistically, MOTS-c:
- Activates AMPK without needing exercise input.
- Translocates to the nucleus under metabolic stress and binds antioxidant response elements.
- Increases glucose uptake in skeletal muscle independent of insulin.
- Drops with age — centenarians have higher MOTS-c than 70-year-olds.
Functionally it behaves like an exercise mimetic with a glucose-disposal bias. In rodents it prevents diet-induced obesity, restores insulin sensitivity, and protects against age-related metabolic decline [2]. In a small human trial in older adults with insulin resistance, MOTS-c at 10 mg subcutaneously three times weekly improved fasting glucose and 2-hour OGTT response [3].
Half-life is short (under an hour in plasma) but the downstream nuclear signaling lasts days. Standard dosing is 10 mg subcutaneous 2–3x weekly, with some athletes pushing to 10 mg daily for short blocks.
Tony Huge laws of biochemistry physics: Same Pathway, Different Lever
One of the Tony huge laws of biochemistry Physics is that two compounds attacking the same problem from different positions are almost always synergistic and rarely additive. 5-Amino-1MQ preserves the substrate. MOTS-c increases the signal. You are not double-dipping — you are filling the tank and stomping the pedal.
Another Law: the route of administration matters more than the molecule when bioavailability is the bottleneck. 5-Amino-1MQ wins on convenience. MOTS-c wins on receptor saturation. If you are pin-shy, start with 5-Amino-1MQ. If you are already injecting GH or testosterone, MOTS-c is a free add-on.
Head-to-Head: Where Each Wins
| Use Case | 5-Amino-1MQ | MOTS-c |
|---|---|---|
| Fat loss, sedentary user | Winner | Modest |
| Glucose disposal, athletic | Modest | Winner |
| Methyl-pool sparing | Winner | Neutral |
| Exercise mimetic effect | None | Winner |
| Convenience | Oral | Subcutaneous |
| Cost per month | ~$60 | ~$200 |
| Data depth | Animal-heavy | Some human |
| Stack with HRT | Excellent | Excellent |
The Natural Plus Protocol: How To Run Each
5-Amino-1MQ standalone: 100 mg once daily, morning, empty stomach. Eight-week block, four-week washout. Pair with 500 mg trimethylglycine to support the methyl pool you are now sparing. Bloodwork at baseline and at week eight: fasting insulin, HOMA-IR, A1c, ALT, AST, lipid panel, CBC, comprehensive metabolic panel.
MOTS-c standalone: 10 mg subcutaneous, three times weekly, morning. Twelve-week block. Reconstitute in bacteriostatic water, store refrigerated, use within 30 days. Bloodwork at baseline and week twelve plus an OGTT if you are insulin-resistant.
Stacked protocol (the actual move): 100 mg 5-Amino-1MQ daily oral + 10 mg MOTS-c subcutaneous 2x weekly. Run for 8 weeks. Combine with the natural plus Protocol foundation — zone-2 cardio four times weekly, protein at 1 g/lb, ten thousand IU vitamin D3, K2-MK7, magnesium glycinate, and consistent sleep. The compounds are pharmacology; the rest is the engine.
Stacking Map
| Stack Partner | Rationale | Notes |
|---|---|---|
| NMN 500 mg | Feeds the precursor pool 5-Amino-1MQ is preserving | Synergy |
| Berberine 1500 mg | AMPK + insulin sensitization | Compounding effect on glucose |
| Retatrutide microdose | GLP-1 + GIP + glucagon — fat-loss multiplier | Watch GI tolerance |
| Methylene blue 5 mg | Mitochondrial electron-shuttle assist | See companion article |
| BPC-157 250 mcg | GI repair, lowers MOTS-c injection-site irritation | Optional |
Target Audience
5-Amino-1MQ is best for the 35-and-up biohacker carrying visceral fat, the post-bulk bodybuilder trying to lean out without crashing testosterone, and the metabolic-syndrome patient who hates injections. MOTS-c is best for the lifter who already trains hard and wants to push glucose into muscle, the older athlete defending mitochondrial output, and anyone running a longevity stack who can tolerate sub-q work.
Timeline of Effects
| Week | 5-Amino-1MQ | MOTS-c |
|---|---|---|
| 1 | Mild appetite shift, urine color change | Energy bump on training days |
| 2–3 | Waist measurement starts dropping | Glucose stability, better pumps |
| 4–6 | Visible fat-loss, fasting glucose improvement | OGTT improvement, body recomp |
| 8 | HOMA-IR shifts measurably | Substantive mitochondrial endurance gain |
Interesting Perspectives
The hypocrisy angle is loud here. The same dietary establishment that screams about peptide research chemicals will, in the same breath, recommend metformin for healthy people off-label for longevity — a drug with a half-century of mitochondrial-toxicity literature behind it. They will recommend statins that crash CoQ10. They will recommend SSRIs for “metabolic syndrome with anxiety” while ignoring the metabolic substrate. 5-Amino-1MQ has a tighter mechanism than metformin. MOTS-c is literally a peptide your own mitochondria already produce. The fear is theatrical.
The cross-domain connection: NNMT inhibition isn’t just about fat. The methyl pool feeds DNA methylation, histamine clearance via HNMT, catecholamine clearance via COMT, and phospholipid synthesis via PEMT. When you stop NNMT from siphoning methyl groups, you indirectly support every one of those pathways. This is why 5-Amino-1MQ users often report calmer histamine response, better cognitive clarity, and improved liver enzymes — it isn’t magic, it’s stoichiometry.
Frequently Asked Questions
Can I run both at once? Yes. The mechanisms do not overlap meaningfully and the side-effect profiles are different. The combined protocol is the rational move for most users serious about metabolic restoration.
Will either crash methylation? 5-Amino-1MQ should improve the methyl pool by sparing nicotinamide. MOTS-c is methyl-neutral. If you supplement TMG you have full coverage.
Do I need to cycle? Yes for 5-Amino-1MQ — eight on, four off is a sensible rhythm. MOTS-c can run continuously but most users do twelve-week blocks separated by a month.
What about NAD+ patches? They are fine as a third lever but they don’t solve the NNMT-overexpression problem and they don’t replicate MOTS-c’s nuclear signaling. They are not substitutes.
References
- Neelakantan H, et al. “Selective and membrane-permeable small molecule inhibitors of NNMT for the treatment of obesity.” Biochem Pharmacol. 2018. PMID: 29555331
- Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015. PMID: 25738459
- Reynolds JC, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nat Commun. 2021. PMID: 33514698
- Kraus D, et al. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature. 2014. PMID: 24717513
- Kim KH, et al. “The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.” Cell Metab. 2018. PMID: 29983246
Where To Go Next
For the foundation that makes either peptide actually work, start with the Enhanced Athlete Protocol hub. For peptide-specific stacking logic, the peptide pillar. For the bloodwork you actually need before running either compound, the bloodwork guide. For metabolic context, the nutrition pillar. If you are still building the engine before you bolt on the pharmacology, the beginners pathway is the right first move.